Sylvester Comprehensive Cancer Center

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • GOG 0278: Cervical - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Jemima Duroseau
    RCphone 3055856408

    IRB: 20150507

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: GOG

    Enrolling Sites:

    Deerfield
    JMH
    Sylvester

    Title:

    ?Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB2 (=2CM) Cervical Cancer?

    Eligibility Criteria - NCT01649089 *This information has been extracted from " www.clinicaltrials.gov"

  • MK-347 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Dayana Deltejo

    IRB: 20160477

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary,Other Female Genital

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients with Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

    Eligibility Criteria - NCT02834975 *This information has been extracted from " www.clinicaltrials.gov"

  • AGEN2034 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170076

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Cervix Uteri

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-700-01: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

    Eligibility Criteria - NCT03104699 *This information has been extracted from " www.clinicaltrials.gov"

  • AL3818-US-002 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Michelle Munevar
    RCphone 3052437530

    IRB: 20170218

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary

    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    AL3818-US-002: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

    Eligibility Criteria - NCT02584478 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170846 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Dayana Deltejo

    IRB: 20170846

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer

    Eligibility Criteria - NCT03367871 *This information has been extracted from " www.clinicaltrials.gov"

  • GOG 3018 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Antonio Marrero

    IRB: 20181014

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary

    Sponsor: GOG Foundation

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    VB-111-701 / GOG-3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

    Eligibility Criteria - NCT03398655 *This information has been extracted from " www.clinicaltrials.gov"

  • C-550-01 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Antonio Marrero

    IRB: 20181020

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: Agenus

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    C-550-01: A Phase 1/2 Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

    Eligibility Criteria - NCT03495882 *This information has been extracted from " www.clinicaltrials.gov"

  • GOG 3032 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Dayana Deltejo

    IRB: 20190586

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary

    Sponsor: Tesaro

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)

    Eligibility Criteria - NCT03955471 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190823 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20190823

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Ovary,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Lung

    Sponsor: Plexxikon

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03297424 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190327 - Kobetz Erin

  • Investigator:
    Erin Kobetz
    RCname Email

    Coordinator:

    IRB: 20190327

    SDG: Population Sciences
    Disease Site(s):

    Cervix Uteri

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Validating a rapid HPV test to increase screening uptake to reduce cervical cancer disparities

  • LN-145 - Lekakis, Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:
    RCemailImg Dayana Deltejo

    IRB: 20161142

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: LBIO

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy ofCell Transfer Therapy Using Autologous Tumor InfiltratingLymphocytes (LN-145) followed by IL-2 in Patients with Recurrentand/or Metastatic Cervical Carcinoma

    Eligibility Criteria - NCT03108495 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer

    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180308 - Schaefer Solle Natasha

  • Investigator:
    Natasha Schaefer Solle
    RCname Email

    Coordinator:

    IRB: 20180308

    SDG: Population Sciences
    Disease Site(s):

    Cervix Uteri

    Sponsor: SCCC

    Enrolling Sites:

    Community Clinics
    Sylvester

    Title:

    Examining the Association between Occupational Chemical Exposures and the effects on the Vaginal Microbiome of Female Firefighters

  • 2018-002872-42 - Schlumbrecht, Matthew

  • Investigator:
    Matthew Schlumbrecht
    RCname Email

    Coordinator:

    IRB: 20190356

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

    Eligibility Criteria - NCT03830866 *This information has been extracted from " www.clinicaltrials.gov"

  • 4010-03-001 - Schlumbrecht, Matthew

  • Investigator:
    Matthew Schlumbrecht
    RCname Email

    Coordinator:
    RCemailImg Dayana Deltejo

    IRB: 20190587

    SDG: Gynecologic Cancer
    Disease Site(s):

    Corpus Uteri

    Sponsor: Tesaro

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)

    Eligibility Criteria - NCT03981796 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • LUD2015-008 - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170230

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary,Colon,Rectum

    Sponsor: LUDWIG INSTITUTE FOR CANCER RESEARCH

    Enrolling Sites:

    Sylvester

    Title:

    LUD2015-008: A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies

    Eligibility Criteria - NCT02963831 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"